| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 25mg |
|
||
| 50mg |
|
||
| Other Sizes |
| Targets |
1. Tyrosinase (key enzyme in melanin biosynthesis, IC50 = 26.7 μM for enzyme activity inhibition) [2]
|
|---|---|
| ln Vitro |
1. Tyrosinase activity inhibition: Mulberroside F exhibited dose-dependent inhibitory activity against mushroom tyrosinase; the IC50 value for inhibiting the enzyme’s monophenolase activity (conversion of L-tyrosine to L-DOPA) was 26.7 μM, and it showed a weaker inhibitory effect on diphenolase activity (conversion of L-DOPA to dopaquinone) with a 32% inhibition rate at 50 μM [2]
2. Melanin biosynthesis inhibition in melanoma cells: In murine B16 melanoma cells, Mulberroside F (10-50 μM) dose-dependently reduced intracellular melanin content; at 50 μM, melanin production was decreased by 48% relative to the control group, with no significant cytotoxicity to B16 cells (cell viability > 90% at concentrations up to 50 μM) [2] |
| Enzyme Assay |
1. Mushroom tyrosinase monophenolase/diphenolase activity assay: The reaction system was established with appropriate concentrations of mushroom tyrosinase, substrate (L-tyrosine for monophenolase or L-DOPA for diphenolase), and serial dilutions of Mulberroside F (0-100 μM) in a buffer solution (pH 6.8). The reaction was initiated by adding the enzyme and incubated at 37℃ for 10 min (monophenolase) or 5 min (diphenolase). The absorbance at 475 nm (for monophenolase) or 490 nm (for diphenolase) was measured using a microplate reader, and the residual enzyme activity was calculated relative to the vehicle control to determine the IC50 value and inhibition rate [2]
|
| Cell Assay |
1. B16 melanoma cell melanin content detection assay: B16 cells were seeded in 6-well plates at a density of 2×10⁵ cells per well and incubated for 24 h to attach. The cells were then treated with different concentrations of Mulberroside F (10-50 μM) for 72 h, with a vehicle control group and a positive control group (arbutin) set in parallel. After treatment, the cells were harvested, washed, and lysed with a lysis buffer containing detergent. The cell lysate was centrifuged, and the absorbance of the supernatant was measured at 405 nm to quantify melanin content; the cell viability was simultaneously detected using a cell viability reagent to exclude the influence of cytotoxicity [2]
|
| References |
|
| Additional Infomation |
Mulberroside F belongs to the benzofuran class of compounds. It has been reported that Mulberroside F exists in white mulberry (Morus alba), and there is relevant data. 1. Mulberroside F is a stilbene glycoside compound, which was isolated from the leaves of white mulberry (Morus alba) by chromatographic separation and purification methods [2]. 2. The anti-melanin production mechanism of Mulberroside F is mainly achieved by inhibiting tyrosinase activity, thereby blocking the rate-limiting step of melanin biosynthesis (L-tyrosine is converted to L-dopa and further oxidized to dopaquinone), thereby reducing the accumulation of melanin in melanoma cells [2]. 3. Due to its tyrosinase inhibitory activity and low cytotoxicity to skin-related cells at effective concentrations, Mulberroside F has potential skin whitening application value in cosmetic formulations. [2]
|
| Molecular Formula |
C26H30O14
|
|---|---|
| Molecular Weight |
566.5080
|
| Exact Mass |
566.163
|
| CAS # |
193483-95-3
|
| PubChem CID |
60208818
|
| Appearance |
White to off-white solid powder
|
| Density |
1.6±0.1 g/cm3
|
| Boiling Point |
920.5±65.0 °C at 760 mmHg
|
| Flash Point |
510.5±34.3 °C
|
| Vapour Pressure |
0.0±0.3 mmHg at 25°C
|
| Index of Refraction |
1.708
|
| Source |
Originated from plants: other families
|
| LogP |
-1.77
|
| Hydrogen Bond Donor Count |
9
|
| Hydrogen Bond Acceptor Count |
14
|
| Rotatable Bond Count |
7
|
| Heavy Atom Count |
40
|
| Complexity |
820
|
| Defined Atom Stereocenter Count |
10
|
| SMILES |
C1=CC2=C(C=C1O[C@H]3[C@@H]([C@H]([C@@H]([C@H](O3)CO)O)O)O)OC(=C2)C4=CC(=CC(=C4)O[C@H]5[C@@H]([C@H]([C@@H]([C@H](O5)CO)O)O)O)O
|
| InChi Key |
YPMOTUXWPXDQDJ-PCIRLDFKSA-N
|
| InChi Code |
InChI=1S/C26H30O14/c27-8-17-19(30)21(32)23(34)25(39-17)36-13-2-1-10-5-15(38-16(10)7-13)11-3-12(29)6-14(4-11)37-26-24(35)22(33)20(31)18(9-28)40-26/h1-7,17-35H,8-9H2/t17-,18-,19-,20-,21+,22+,23-,24-,25-,26-/m1/s1
|
| Chemical Name |
(2R,3S,4S,5R,6S)-2-(hydroxymethyl)-6-[[2-[3-hydroxy-5-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyphenyl]-1-benzofuran-6-yl]oxy]oxane-3,4,5-triol
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture and light. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
Ethanol: ~5 mg/mL (~8.8 mM; with ultrasonication)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 0.5 mg/mL (0.88 mM) (saturation unknown) in 10% EtOH + 40% PEG300 + 5% Tween-80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), Clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of ethanol stock solution (5.0 mg/mL) to 400 μL of PEG300 and mix well; then add 50 μL of Tween-80 and mix well; finally add 450 μL of physiological saline and adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 0.5 mg/mL (0.88 mM) (saturation unknown) in 10% EtOH + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), Clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of ethanol stock solution (5.0 mg/mL) to 900 μL of 20% SBE-β-CD physiological saline and mix well. Preparation of 20% SBE-β-CD physiological saline (4°C, store for one week): Dissolve 2 g of SBE-β-CD powder in 10 mL of physiological saline until completely dissolved and clear. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. Solubility in Formulation 3: ≥ 0.5 mg/mL (0.88 mM) (saturation unknown) in 10% EtOH + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), Clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of EtOH stock solution (5.0 mg/mL) to 900 μL of corn oil and mix well. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.7652 mL | 8.8260 mL | 17.6519 mL | |
| 5 mM | 0.3530 mL | 1.7652 mL | 3.5304 mL | |
| 10 mM | 0.1765 mL | 0.8826 mL | 1.7652 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
